John Joseph Johnston Sells 3,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $4.64, for a total value of $13,920.00. Following the transaction, the director now directly owns 141,950 shares in the company, valued at approximately $658,648. This trade represents a 2.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

John Joseph Johnston also recently made the following trade(s):

• On Thursday, December 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The shares were sold at an average price of $4.01, for a total value of $12,030.00.

MaxCyte Trading Down 0.9 %

NASDAQ MXCT opened at $4.64 on Thursday. The company has a market cap of $490.49 million, a P/E ratio of -13.65 and a beta of 1.29. The company has a fifty day simple moving average of $4.20 and a 200 day simple moving average of $4.08. MaxCyte, Inc. has a 12-month low of $3.16 and a 12-month high of $5.29.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The firm had revenue of $8.16 million during the quarter, compared to analysts’ expectations of $7.50 million. During the same period last year, the company earned ($0.11) earnings per share. Sell-side analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

Institutional Trading of MaxCyte

Several institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC bought a new stake in MaxCyte during the third quarter worth $51,000. China Universal Asset Management Co. Ltd. boosted its holdings in MaxCyte by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock worth $79,000 after acquiring an additional 7,930 shares during the last quarter. Verition Fund Management LLC grew its stake in shares of MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after acquiring an additional 6,045 shares in the last quarter. Creative Planning raised its holdings in shares of MaxCyte by 33.6% in the third quarter. Creative Planning now owns 28,652 shares of the company’s stock valued at $111,000 after purchasing an additional 7,212 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of MaxCyte by 84.5% during the third quarter. SG Americas Securities LLC now owns 37,969 shares of the company’s stock valued at $148,000 after purchasing an additional 17,385 shares in the last quarter. 68.81% of the stock is owned by hedge funds and other institutional investors.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.